🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢CALL FOR PAPERS📢 Submit to the #BJPsych 2024 themed issue "Pathway to Delivery of Dementia Disease Modification". With guest editors Ivan Koychev Bart Sheehan Paresh Malhotra @drjudeharrison Dag Aarsland Find out more: bit.ly/3KMHtoR Cambridge UP - Psychology & Psychiatry Royal College of Psychiatrists

📢CALL FOR PAPERS📢 Submit to the #BJPsych 2024 themed issue "Pathway to Delivery of Dementia Disease Modification". With guest editors Ivan Koychev Bart Sheehan Paresh Malhotra @drjudeharrison Dag Aarsland Find out more: bit.ly/3KMHtoR Cambridge UP - Psychology & Psychiatry Royal College of Psychiatrists

A big milestone today Oxford Psychiatry as we complete the first randomisation visit for the ISAP trial. My thanks to the study participants, CRF team (represented by Amanda and Rachel), the Oxford Diabetes Trial Unit Amanda I Adler , Dementias Platform UK, Oxford Health Biomedical Research Centre, and Novo Nordisk

Come to Cambridge University for exciting research against dementia ! Post doc jobs.cam.ac.uk/job/39152/ Research Assistant jobs.cam.ac.uk/job/43768/ In Dementias Platform UK and MRC Cognition and Brain Sciences Unit projects funded by Medical Research Council to study #MEG #EEG and cognition in #Alzheimers MEG UK Please share

The new WHO guidelines (mhGAP) for depression are ridiculous! AD:s get a conditional recommendation to be "considered" for moderate to severe depression with low certainty of evidence while psychological therapies - as a group - get a strong recommendation to be "offered" ->

New work from PHOSP-COVID study ⬇️ academic.oup.com/braincomms/adv… Maxime Taquet Ivan Koychev 🧠 ‘ongoing neuropsychiatric symptoms are not due to ongoing neural injury’

Join our team - a research assistant position working on the Deep and Frequent Phenotyping study exploring biomarkers of Alzheimer’s disease at its earliest stages University of Oxford Oxford Psychiatry my.corehr.com/pls/uoxrecruit…

This study should be retracted, both for issues the authors can address and issues with the underlying data. Short thread.

Two world-class research teams – based at UCL & Dementias Platform UK at University of Oxford - will carry out UK-wide clinical trials to identify blood tests to boost dementia diagnosis. We hope this will lead to blood tests for diagnosing Alzheimer’s & other forms of dementia becoming

ALZHEIMER'S DRUG PROPOSALS WANTED!! I'm delighted that National Institute for Health and Care Research are funding development of a UK platform trial for people with symptomatic AD. This is a partnership between MRC Clinical Trials Unit at UCL & Dementias Platform UK + many others, & supported by Research at ARUK Alzheimer's Society UK Dementia Research Institute. Please RT!

NEW PAPER: Neurological & psychiatric outcomes of semaglutide for Type II diabetes. Study Riccardo De Giorgi Maxime Taquet finds semaglutide: - does not negatively impact brain health - is associated with lower risk of cognitive problems & nicotine dependence psych.ox.ac.uk/news/new-study…

PhD opportunity to work with me and Vanessa Raymont Oxford Psychiatry on epigenetic and proteomic biomarkers of neurodegeneration. The work will be done in collaboration with the cfdx company which leads the way in AI-enabled liquid biopsy for dementia tinyurl.com/bdfnvyh5

Need a power/sample size calculation for a study or upcoming grant? Led by Emil Hodzic-Santor, we built a simple, free, and pain-free (!) shiny app. feedback welcome plz share with interested parties. check it out: powercalc.ca 🦾🤓 Michelle Sholzberg Kieran Campbell Lianne Jeffs

Thought-provoking work! Adam Neurodegenerative fluid biomarkers are enriched in human cervical lymph nodes academic.oup.com/brain/article/…

Just out - we summarise methods for assessing brain insulin function in humans. Superb work by former PhD student Graham Reid sciencedirect.com/science/articl…

Our new open-access paper “Glucagon- like peptide- 1 receptor agonists for major neurocognitive disorders” jnnp.bmj.com/content/early/… on Journal of Neurology, Neurosurgery and Psychiatry